CDK4 and meningioma: In line, the FAK inhibitor GSK2256098 is being evaluated in patients with progressive meningioma in a still recruiting multi-arm phase 2 trial (Alliance A071401, NCT02523014) along with the cyclin-dependent kinase 4/6 inhibitor abemaciclib, the AKT inhibitor capivasertib, and the sonic hedgehog (SHH) inhibitor vismodegib.